How were Cubist Pharmaceuticals' earnings last quarter?

Cubist Pharmaceuticals Inc (NASDAQ:CBST) released its earnings results on Tuesday, October, 21st. The biopharmaceutical company reported $0.58 EPS for the quarter, topping analysts' consensus estimates of $0.04 by $0.54. The biopharmaceutical company had revenue of $309.20 million for the quarter, compared to analysts' expectations of $305.50 million. The firm's revenue for the quarter was up 16.2% on a year-over-year basis. During the same period in the prior year, the firm earned $0.41 EPS.

What other stocks do shareholders of Cubist Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cubist Pharmaceuticals investors own include Intercept Pharmaceuticals (ICPT) , Ionis Pharmaceuticals (IONS) , Netflix (NFLX) , Novavax (NVAX) , (QIHU) (QIHU) , Seagen (SGEN) , Bausch Health Companies (BHC) , Baidu (BIDU) , Booking (BKNG) and BioMarin Pharmaceutical (BMRN) .

NASDAQ:CBST

Cubist Pharmaceuticals (CBST) Stock Price, News & Analysis

→ AI “wealth window” is closing soon! (From Paradigm Press) (Ad)

Free CBST Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Today's Range: N/A
50-Day Range: N/A
52-Week Range: N/A

Volume: N/A
Average Volume: N/A
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Cubist Pharmaceuticals alerts:

Ad Paradigm Press

AI “wealth window” is closing soon!

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

I put together this personal video [HERE]…

About Cubist Pharmaceuticals Stock (NASDAQ:CBST)

Cubist Pharmaceuticals, Inc. (Cubist) is a biopharmaceutical company focused on the research, development and commercialization of therapies to treat serious medical conditions in acutely ill patients who are hospitalized or are being treated in other acute care settings. As of December 31, 2011, the Company had two marketed products, CUBICIN (daptomycin for injection) and ENTEREG (alvimopan). The Company also co-promotes DIFICIDTM in the United States, under its co-promotion agreement with Optimer Pharmaceuticals, Inc. (Optimer). In September 2013, the Company announced that it has completed the acquisition of Trius Therapeutics Inc. In October 2013, the Company announced that it has completed its acquisition of Optimer Pharmaceuticals, Inc.

Ad Paradigm Press

AI “wealth window” is closing soon!

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

I put together this personal video [HERE]…

CBST Stock News Headlines

April 11, 2024 | bbc.co.uk

Key facts about Cubism

January 13, 2024 | seekingalpha.com

CBST:CA The Cannabist Company Holdings Inc.

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

May 16, 2023 | bbc.co.uk

What is Cubism?

April 7, 2023 | thestreet.com

Cubist Stock Hits New 52-Week High (CBST)

March 30, 2023 | thestreet.com

Cubist Rises On Unusually High Volume (CBST)

March 18, 2023 | thestreet.com

Tetraphase Antibiotic Nearing Key Tolerability Test

March 11, 2023 | benzinga.com

Cubist Raises $7M to Make dApp Development More Efficient, Secure, and Scalable

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

March 4, 2023 | thestreet.com

Tetraphase: Another Good Investment In Hot Antibiotic Market

December 17, 2022 | thestreet.com

Cubist Pharmaceuticals (CBST) Stock Skyrockets Today on $8.4 Billion Merck Deal

See More Headlines

Receive CBST Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cubist Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 10/21/2014
Today: 4/19/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: N/A
Industry: N/A
Sub-Industry: Biotechnology
Current Symbol: NASDAQ:CBST
CUSIP: 22967810
CIK: 912183
Web: www.cubist.com
Phone: +1-781-8608660
Fax: N/A
Employees: N/A
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

CBST Stock Analysis - Frequently Asked Questions

How were Cubist Pharmaceuticals' earnings last quarter?: Cubist Pharmaceuticals Inc (NASDAQ:CBST) released its earnings results on Tuesday, October, 21st. The biopharmaceutical company reported $0.58 EPS for the quarter, topping analysts' consensus estimates of $0.04 by $0.54. The biopharmaceutical company had revenue of $309.20 million for the quarter, compared to analysts' expectations of $305.50 million. The firm's revenue for the quarter was up 16.2% on a year-over-year basis. During the same period in the prior year, the firm earned $0.41 EPS.
What other stocks do shareholders of Cubist Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Cubist Pharmaceuticals investors own include Intercept Pharmaceuticals (ICPT), Ionis Pharmaceuticals (IONS), Netflix (NFLX), Novavax (NVAX), (QIHU) (QIHU), Seagen (SGEN), Bausch Health Companies (BHC), Baidu (BIDU), Booking (BKNG) and BioMarin Pharmaceutical (BMRN).

This page (NASDAQ:CBST) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Cubist Pharmaceuticals (CBST) Stock Price, News & Analysis

About Cubist Pharmaceuticals Stock (NASDAQ:CBST)

CBST Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

CBST Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info